Results 101 to 110 of about 35,525 (153)

Comment on Bellapu, Dhanush, et al., sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus.

Indian J Pharmacol
Dhande P, Jaiswal S, Dawane JS, Shukla CD.   +3 more
europepmc   +1 more source

Could Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists Play a Role in Gout Treatment? [PDF]

Pharmaceutics
Kaufmann D, Schlesinger N.
europepmc   +1 more source

Safety and Effectiveness of Sodium-Glucose Co-Transporter 2 Inhibitors in Active Cancer Patients with Heart Failure: Results of the Observational TOSCA Trial. [PDF]

J Cardiovasc Dev Dis
Canale ML, Fabiani I, Delle Donne MG, Chianca M, Barletta V, Capati E, Solinas M, Frediani L, Venturini E, Arena G, Zucchelli G, Pasanisi EM, Amoroso D, Allegrini G, De Caterina R, Emdin M, Camerini A.   +16 more
europepmc   +1 more source

Methodological and Statistical Concerns Regarding "Can Sodium-Glucose Co-Transporter-2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure?" [PDF]

Clin Cardiol
Gupta R, Vohra S, Yadav A, Gupta N, Mody R.   +4 more
europepmc   +1 more source

Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrences After Catheter Ablation in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Parsi S, Sonavane K, Ravi U, Shirsat PD, Chamarthi VS, Gabr M, Ponnam HC, Surani S, Bansal V, Kashyap R.   +9 more
europepmc   +1 more source

Localization of the therapeutic targets for endothelin receptor antagonists and sodium-glucose co-transporter 2 inhibitors in the chronic liver disease, primary sclerosing cholangitis. [PDF]

Front Pharmacol
Kuc RE, Paterson AL, Williams TL, Gelson WTH, Greasley PJ, Ambery P, Maguire JJ, Davenport AP.   +7 more
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease. [PDF]

Eur Heart J
Ostrominski JW, Højbjerg Lassen MC, Claggett BL, Miao ZM, Inzucchi SE, Docherty KF, Desai AS, Jhund PS, Køber L, Ponikowski P, Sabatine MS, Lam CSP, Martinez FA, de Boer RA, Hernandez AF, Shah SJ, Petersson M, Langkilde AM, McMurray JJV, Solomon SD, Vaduganathan M.   +20 more
europepmc   +1 more source

Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats. [PDF]

Front Vet Sci
Vieira AB, Cavanaugh SM, Ciambarella BT, Machado MV.   +3 more
europepmc   +1 more source

Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study. [PDF]

Diabetes Obes Metab
Tang WC, Reynier P, Douros A, Yu OHY, Platt RW, Filion KB.   +5 more
europepmc   +1 more source

Sodium-glucose co-transporter-2 inhibitors vs metformin in reducing osteoarthritis risk: a retrospective cohort study of health insurance claims and check-up data. [PDF]

JBMR Plus
Hatano M, Sasabuchi Y, Okada A, Ishikura H, Tanaka T, Saito T, Tanaka S, Yasunaga H.   +7 more
europepmc   +1 more source